Long-term real-world data of ustekinumab in ulcerative colitis: the Stockholm Ustekinumab Study (STOCUSTE)

• Published in: European journal of gastroenterology & hepatology Vol. 36; no. 12; p. 1419
• Main Authors: Sabhan, Haider, Bello, Francesca, Muhsen, Samer, Borin, Alexandra, Johansson, Fredrik, Höög, Charlotte, Forsberg, Ole, Wennerström, Christina, Lördal, Mikael, Almer, Sven, Söderman, Charlotte
• Format: Journal Article
• Language: English
• Published: England 01.12.2024
• Subjects: Adult; Aged; Colitis, Ulcerative - drug therapy; Female; Gastrointestinal Agents - adverse effects; Gastrointestinal Agents - therapeutic use; Humans; Male; Middle Aged; Remission Induction; Retrospective Studies; Severity of Illness Index; Sweden; Time Factors; Treatment Outcome; Ustekinumab - therapeutic use; Sweden
• ISSN: 1473-5687
• DOI: 10.1097/MEG.0000000000002854

Ustekinumab (UST) is an anti-interleukin-12/23 antibody used in the treatment of inflammatory bowel disease. This study includes patients treated at four hospitals in Stockholm to provide long-term real-world data. Retrospective study including patients diagnosed with ulcerative colitis and treated with UST between the years 2019 and 2021. Patients were followed until withdrawal of treatment, or until a predefined end of study, 31 July 2021. Disease activity was assessed with Physician Global Assessment (PGA); Ulcerative Colitis Endoscopic Index of Severity (UCEIS), laboratory parameters, and drug persistence. The primary outcome was steroid-free remission (PGA = 0) and response (decrease PGA ≥ 1 from baseline) at 3 and 12 months, respectively. A total of 96 patients, 44 women and 52 men were included. The patients had either extensive colitis (69%), left-sided colitis (29%), or proctitis (3%). All but two patients were anti-TNF-experienced; 94 (98%) had failed ≥1, 59 (61%) ≥ 2, and 34 (35%) had failed ≥ 3 anti-TNF drugs. In addition, 28 (29%) had failed vedolizumab. At inclusion, 92/96 patients (96%) had active disease and four patients were in remission. Among patients who were treated with UST, 9/71 (13%) were in steroid-free remission at 3 months, and 26/33 (78%) were at 12 months. Withdrawal rates at 3 and 12 months, were 12 and 26%, respectively, mainly due to persisting disease activity (20%). In this group of patients with difficult-to-treat ulcerative colitis, UST was shown to be effective in the majority, with high drug persistence at 12 months in combination with a favorable safety profile.